| 摘要: |
| ［摘要］ 目的 分析子宫内膜样腺癌（EA）患者的多功能蛋白聚糖(VCAN)和血清癌抗原125（CA125）表达情况及其与临床病理特征的关联性。方法 选择2016-01～2019-01在该院接受门诊宫腔内膜组织取检患者120例，其中EA患者60例（EA组），不典型子宫内膜增生患者40例（不典型子宫内膜增生组），正常子宫内膜者20例（正常子宫内膜组）。比较三组患者的VCAN和血清CA125水平。分析EA患者的VCAN和血清CA125表达情况与临床病理特征的关联性。结果 EA组、不典型子宫内膜增生组和正常子宫内膜组在VCAN及血清CA125的阳性率方面比较差异有统计学意义（P<0.05）；且在三组中，EA组的VCAN及血清CA125的阳性率均为最高。VCAN阳性表达的EA患者手术分期为Ⅲ/Ⅳ期、浸润深度>1/2、出现淋巴结转移的人数比例大于VCAN阴性表达者，差异有统计学意义（P<0.05）。血清CA125阳性表达的EA患者手术分期为Ⅲ/Ⅳ期及出现淋巴结转移的人数比例大于血清CA125阴性表达者，差异有统计学意义（P<0.05）。EA患者VCAN与血清CA125表达情况具有差异性（P=0.000）。结论 VCAN和血清CA125对EA的发生与发展具有重要作用，其为EA的早期诊断及治疗方案的选择提供了参考。 |
| 关键词: 多功能蛋白聚糖 血清癌抗原125 子宫内膜样腺癌 |
| DOI：10.3969/j.issn.1674-3806.2020.07.08 |
| 分类号:R 737.33 |
| 基金项目:广西医疗卫生适宜技术开发与推广应用项目（编号：S2017086） |
|
| Correlations between versican and serum CA125 expressions and clinicopathological characteristics in patients with endometrioid adenocarcinoma |
|
LI Jing-ling, WEI Hai-ming, ZHAO Ren-feng, et al.
|
|
Department of Gynecology, the People′s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Objective To analyze the expressions of versican(VCAN) and serum cancer antigen 125(CA125) in patients with endometrioid adenocarcinoma(EA) and their correlations with clinicopathological characteristics. Methods One hundred and twenty outpatients receiving endometrial tissue examination at our hospital from January 2016 to January 2019 were selected, including 60 patients with EA(EA group), 40 patients with atypical endometrial hyperplasia(atypical endometrial hyperplasia group), and 20 patients with normal endometrium(normal endometrial group). The levels of the patients′ VCAN and serum CA125 were compared among the three groups. The correlations between VCAN and serum CA125 expressions and clinicopathological characteristics were analyzed in the EA patients. Results There were significant differences in the positive rates of VCAN and serum CA125 among the EA group, the atypical endometrial hyperplasia group and the normal endometrial group(P<0.05), and the positive rates of VCAN and serum CA125 of the EA group were the highest in the three group. The proportion of the VCAN positive expression EA patients with surgical grade Ⅲ/Ⅳ, infiltration depth >1/2 and lymph node metastasis was significantly higher than that of the VCAN negative expression EA patients(P<0.05). The proportion of the serum CA125 positive expression EA patients with surgical grade Ⅲ/Ⅳ and lymph node metastasis was significantly higher than that of the serum CA125 negative expression EA patients(P<0.05). There was significant difference between the expression of VCAN and the expression of serum CA125 in the EA patients(P=0.000). Conclusion VCAN and serum CA125 play an important role in the occurrence and development of EA. They provide a reference for the early diagnosis and treatment options of EA. |
| Key words: Versican(VCAN) Serum cancer antigen 125(CA125) Endometrioid adenocarcinoma(EA) |
